Make Informed Investment Decisions with Affordable Access to Experts
A 3rd View: Examining the market potential of DBV's Viaskin Patch and Aimmune’s AR-101 with an allergist at an academic institutionTicker(s): AIMT, DBVT
Name: Dr John Lee - MD
Institution: Boston Children's | Harvard
- Clinical Director, Food Allergy Program; Allergy Director, Eosinophilic Gastrointestinal Disease (EGID) Program at Boston Children's & Instructor in Pediatrics, Harvard Medical School.
- Currently manages 500-750 patients with peanut allergy and 500 children with milk allergy.
- Co-investigators in food allergy desensitization programs at Boston Children's Hospital & co-creator of AllergyHome.org.
What % of your patients would you anticipate wanting to use AR101 if approved?Added By: joe_mccann
Can you give us your opinion as to how the safety vs benefit balance between the two drugs?
Is there still a need for a different treatment option or do these two potential entries to market cover most all patient cases you see?Added By: joe_mccann
How does the route of administration factor into treatment decision making? more specifically, for the pediatric audience?Added By: joe_mccann
Please describe your clinical background and how you currently manage your peanut allergy patients.Added By: joe_mccann
Will there be options for patients using one product to be able to switch to another product during maintenance phase?Added By: userb298024d
Will there be room in the market for additional products targeting peanut allergy? For example, one company has recently announced a toothpaste containing peanut proteins, which may support long term maintainence.Added By: userb298024d
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.